LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Status:
Terminated
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
This trial will investigate the combination of two anti-cancer agents to treat patients with
relapsed/refractory small cell lung cancer (SCLC) and ovarian cancers. Oral topotecan has US
FDA approval for treating select gynecological cancers and SCLC. LCL161 is an investigational
product that has been shown in clinical trials to work together with other anti-cancer
agents. In this trial, investigators will determine the optimal dose of LCL161 and topotecan
to administer to patients with relapsed/refractory SCLC and ovarian cancers, and examine the
safety profile of the drug combination.